How Does Cannabis Affect Epilepsy? CBD, THC & Seizure Research Explained

Note: Cannabis is for adults 19+ in Ontario. This content is for informational purposes only and is not medical advice. Consult a healthcare professional for cannabis-related health questions.

Cannabis and epilepsy is one of the most-researched topics in cannabinoid science, and it's a question our budtenders hear weekly, often from family members of someone newly diagnosed. The short version: cannabidiol (CBD), one of the two major cannabinoids in cannabis, has shown measurable effects on certain rare seizure disorders in clinical trials, and Health Canada has approved a CBD-based prescription drug called Epidiolex for specific epilepsy syndromes. THC, the intoxicating compound, has a more complicated relationship with seizures and is generally not the focus of epilepsy research.

This article walks through what the research actually shows, how Canada's medical cannabis system works for epilepsy patients, and why recreational cannabis product categories at Ashario Cannabis are not a substitute for prescribed treatment. We'll also explain the difference between high-CBD flower available at our four Ontario stores and pharmaceutical-grade CBD prescribed by a neurologist.

What does the research say about cannabis and epilepsy?

Research on cannabis and epilepsy has focused almost entirely on CBD, not THC. Multiple randomized controlled trials published between 2017 and 2024 found that purified CBD reduced seizure frequency by roughly 36-44% in patients with Dravet syndrome and Lennox-Gastaut syndrome: two rare, treatment-resistant childhood epilepsies. These findings led to Health Canada approving Epidiolex (a 100 mg/mL CBD oral solution) in 2018.

The strongest evidence supports CBD for these specific syndromes:

• Dravet syndrome: a rare genetic epilepsy beginning in infancy
• Lennox-Gastaut syndrome: a severe childhood-onset epilepsy
• Tuberous sclerosis complex: added to Epidiolex's indications in 2020

For more common forms of epilepsy in adults, evidence is weaker and clinical guidelines from organizations like the Canadian League Against Epilepsy still recommend conventional anti-seizure medications as first-line treatment. According to Health Canada, cannabis is not approved as a stand-alone epilepsy treatment outside of Epidiolex. As of 2026, no recreational cannabis product sold at any Ashario store location is labelled or sold for medical use.

How does CBD work for seizures at the brain level?

CBD appears to reduce seizure activity through multiple mechanisms unrelated to the endocannabinoid system's CB1 and CB2 receptors. Researchers have identified at least three pathways: modulation of GPR55 receptors, desensitization of TRPV1 channels, and inhibition of adenosine reuptake. Unlike THC, CBD doesn't bind strongly to CB1 receptors in the brain, which is why it's non-intoxicating.

This receptor-independent action matters clinically. It means CBD doesn't produce the cognitive effects of THC, and pediatric patients in trials tolerated daily doses up to 20 mg/kg of body weight. For a 30 kg child, that's 600 mg of pure CBD per day: far higher than typical recreational doses. Our Ashario Cannabis blog covers cannabinoid science in more depth across other articles.

It's worth noting: high-CBD flower or oils from a recreational retailer are not equivalent to pharmaceutical CBD. Epidiolex is a 99%+ purified isolate with consistent batch dosing. Recreational CBD oils and flower contain variable cannabinoid ratios, trace THC, and are dosed in much smaller quantities suited to general wellness, not seizure control.

What about THC and epilepsy research?

THC's relationship with seizures is far less clear than CBD's. Pre-clinical animal studies have shown mixed results: some suggest low-dose THC may have anticonvulsant properties via CB1 receptor activation, while higher doses or sudden withdrawal may actually lower seizure threshold in certain models. Human clinical trials specifically for THC and epilepsy are limited.

What is clearer: heavy chronic THC use followed by abrupt cessation has been associated with rare cases of withdrawal seizures, though this is uncommon. For most adults using cannabis recreationally, moderate THC consumption does not appear to trigger seizures in people without an underlying seizure disorder. People with diagnosed epilepsy should always discuss any cannabis use with their neurologist before purchasing products at Ashario or any other retailer.

Some patients and caregivers report that balanced THC:CBD ratios (commonly 1:1 or 1:20) work better than CBD alone: a phenomenon often attributed to the "entourage effect." Evidence for this in epilepsy specifically remains observational rather than from controlled trials. If you have questions about ratio-based products, our budtenders at the Centerpoint Mall location at 6464 Yonge St can show you what's currently on the shelf.

How do you access medical cannabis for epilepsy in Canada?

Medical cannabis in Canada is accessed through a separate stream from recreational stores. Patients require a medical document from an authorized healthcare practitioner, which they then register with a federally licensed seller under the Cannabis Regulations. As of 2026, there are over 100 Health Canada-licensed medical cannabis producers shipping directly to patients.

The process generally looks like this:

1. Consult your family doctor or neurologist about whether cannabis is appropriate
2. If suitable, obtain a medical document specifying daily gram amount and duration (up to 12 months)
3. Register with a licensed producer or apply to grow personally under Section 14 of the Cannabis Regulations
4. Receive products via mail directly from the LP

For Epidiolex specifically, the route is different. It's a prescription drug filled at a pharmacy, not a cannabis dispensary. Ontario's recreational system, regulated by the AGCO, does not handle medical cannabis. Recreational retailers like Ashario Cannabis sell to adults 19+ for personal, non-medical use only.

What CBD dosage is used in epilepsy clinical trials?

Clinical trial dosing for CBD in epilepsy is dramatically higher than typical recreational use. The standard starting dose in pivotal trials was 5 mg/kg/day, titrated up to 10-20 mg/kg/day over several weeks. For context, a recreational CBD oil bottle at a retailer typically contains 30 mg/mL total, with usual single doses of 5-25 mg.

Here's the dosing scale comparison:

• Recreational CBD dose (general wellness): 5-25 mg per use
• Recreational daily cap (Ontario): typically 200-400 mg/day from available products
• Clinical trial dose (pediatric epilepsy): 300-600+ mg/day pure CBD
• Epidiolex maintenance dose: 10 mg/kg twice daily (20 mg/kg/day)

This gap is why we always tell customers shopping for high-CBD products at Ashario that recreational CBD is not a replacement for prescribed seizure medication. Trying to hit a therapeutic anticonvulsant dose through recreational oils would require dozens of bottles per month and still wouldn't deliver pharmaceutical-grade consistency.

Are there high-CBD products available at Ashario Cannabis?

Yes, Ashario carries CBD-dominant flower, oils, capsules, and softgels at all four Ontario locations. Common formats include 1:30 THC:CBD oils (roughly 1 mg THC and 30 mg CBD per mL), 20:1 CBD:THC capsules, and high-CBD flower cultivars with 8-15% CBD and under 1% THC. Inventory rotates based on Licensed Producer supply.

Brands frequently stocked include Solei, Tweed, Aurora Drift, and Stewart Farms: covered in more detail in our cannabis brand reviews. Pure Sunfarms and Redecan also produce balanced ratio oils. For first-time CBD shoppers, our budtenders at the Finch & Dufferin store at 1111A Finch Ave W typically recommend starting with a 1:1 or 20:1 CBD-dominant oil for accurate sublingual dosing.

If you have specific questions about what's in stock today, the fastest route is to call ahead: the Aurora store at 905-503-6770 or Thornton at 249-733-9333 can check shelf inventory in real time. You can also reach our team through the Ashario contact page.

What are the risks of using cannabis with epilepsy medications?

Drug interactions between CBD and common anti-seizure medications are well-documented and clinically significant. CBD inhibits the cytochrome P450 enzymes CYP3A4 and CYP2C19, which metabolize many anticonvulsants. This can raise blood levels of medications like clobazam, valproate, and warfarin, sometimes requiring dose adjustments under medical supervision.

The most studied interaction is with clobazam. CBD can increase active metabolite levels by 3-5x, intensifying sedation. Liver enzyme elevations have also been reported in roughly 5-20% of patients on combined CBD and valproate. This is precisely why epilepsy patients should never self-medicate with recreational cannabis. Anyone managing seizures must coordinate any cannabis use with their prescribing neurologist and have liver function monitored.

Youth and pediatric use is a separate concern. Organizations like Drug Free Kids Canada emphasize that recreational cannabis is not appropriate for anyone under 19, and pediatric epilepsy treatment must remain under specialist care.

Frequently Asked Questions

Can CBD stop a seizure in progress?

No. CBD is not a rescue medication and cannot abort an active seizure. Pharmaceutical CBD (Epidiolex) is used as a daily preventive treatment to reduce seizure frequency over weeks and months, not as an emergency intervention. For seizures lasting more than 5 minutes or clusters of seizures, conventional rescue medications like benzodiazepines prescribed by a neurologist are the standard of care. Call 911 for any prolonged seizure.

Is medical cannabis covered by OHIP in Ontario?

OHIP does not cover medical cannabis directly. Some private insurance plans, Veterans Affairs Canada, and certain workplace benefits programs do reimburse medical cannabis costs with a valid medical document. Epidiolex, as a Health Canada-approved prescription drug, may be covered under the Ontario Drug Benefit or private drug plans depending on the patient's situation. Patients should contact their insurance provider for specifics.

What's the difference between Epidiolex and CBD oil from a dispensary?

Epidiolex is a prescription pharmaceutical containing 100 mg/mL of purified CBD isolate with batch-tested consistency, prescribed for specific seizure disorders. Recreational CBD oil from Ashario or any Ontario retailer typically contains 30 mg/mL or less, may include trace THC, and is sold for adult personal use without medical claims. The two products are not interchangeable, and you cannot achieve therapeutic anticonvulsant dosing with recreational oils alone.

Can recreational cannabis trigger seizures?

For most adults without epilepsy, moderate cannabis use is not associated with seizures. However, in rare cases, very high THC doses, synthetic cannabinoids, or abrupt cessation after heavy chronic use have been linked to seizure activity. People with a personal or family history of epilepsy should discuss any cannabis use with their doctor before purchasing. According to Health Canada, individual responses vary and starting low is always recommended.

What ratio of CBD to THC is best for someone exploring cannabis with an epilepsy history?

There's no universal answer, and this decision should involve a neurologist. That said, products with high CBD and minimal THC (such as 20:1 or 30:1 CBD:THC ratios) are typically the starting point in observational reports. These minimize intoxication and CB1 receptor activation. Ashario stocks several such options including oils and capsules from licensed Canadian producers. Our budtender team can point you to current inventory, but cannot provide medical advice.

Where can I learn more about Canadian cannabis regulations?

The most authoritative sources are Health Canada's cannabis page for federal regulations and product safety, the AGCO website for Ontario retail rules, and Statistics Canada's Cannabis Stats Hub for usage data. For peer-reviewed epilepsy research specifically, the Canadian League Against Epilepsy and Epilepsy Canada publish clinical position statements that summarize current evidence. Ashario's blog focuses on retail and product information, not medical guidance.